Aetna Eating Disorders Coverage & Policy Update

inv-01: Assessment (Medically necessary)

Medically necessary when ALL of the following assessment components are documented:

Assessment components: Complete medical evaluation including detailed history and physical examination; psychiatric or psychological consultation and testing; blood count and serum chemistry (e.g., CBC, electrolytes, BUN/creatinine); liver function tests; urinalysis; electrocardiography; bone density measurement for evaluation of anorexic members.

Documentation should include results and clinical interpretation; bone density testing targeted to anorexic patients as noted.

inv-02: Treatment (Medically necessary)

Covered treatments when clinically indicated and documented:

Core treatments: Nutritional counseling with a graduated eating plan tied to specific weight goals; psychotherapy (eg, cognitive behavioral therapy, family psychotherapy, interpersonal psychotherapy, psychodynamic psychotherapy); pharmacotherapy as appropriate to diagnosis (eg, SSRIs and antipsychotics in anorexia; fluoxetine, TCAs, trazodone, topiramate for bulimia; lisdexamfetamine for binge-eating disorder)

Pharmacotherapy subject to formulary restrictions and plan benefit exclusions for weight‑altering medications; enteral nutrition only as a last resort for anorexia.

inv-03: Experimental / Investigational (Not established)

The following services are considered experimental and investigational (not established) due to insufficient evidence:

Assessment - Experimental/Investigational: Routine screening of asymptomatic adolescents and adults for eating disorders; blood-based serotonergic biomarkers; brain imaging (MRI, PET, SPECT) for diagnosis or treatment tailoring; genotyping for COMT, ESR1, 5-HTTLPR, MC4R and other polymorphisms; EEG for management; gustatory/olfactory testing; Individual Optimal Nutrition (ION) profiling; measurement of peripheral biomarkers (BDNF, adiponectin, hypothalamic neuropeptides, polyunsaturated fatty acids); serum zinc measurement.

Listed as experimental/investigational for diagnosis and treatment.

Treatment - Experimental/Investigational: Acamprosate; acupuncture; cannabinoids; cholinesterase inhibitors; chromium; deep brain stimulation for treatment‑refractory anorexia; DHEA; electroconvulsive therapy; estrogen/HRT for bone in AN; e‑therapy (internet/mobile apps); biofeedback/neurofeedback; food‑specific inhibition training; ghrelin agonists; GLP‑1 receptor agonists; intranasal naloxone; liraglutide; melatonergic medications for night eating; music therapy; neural therapy (superficial injection); oral contraceptives for bone loss prevention; oxytocin; phentermine/topiramate ER (Qsymia); relaxation therapy; repetitive TMS; Mandometer residential treatment; transcranial direct current stimulation (tDCS).

Listed as experimental/investigational for treatment.

inv-04: Coverage-considerations based on evidence

Evidence-based considerations and implied coverage positions:

Pharmacotherapy for bulimia: Fluoxetine is the only medication with regulatory approval for bulimia nervosa; fluoxetine and evidence‑based psychotherapy should be considered first‑line.

From evidence reviews and guideline summaries.

Pharmacotherapy for anorexia: No medications have proven efficacy for acute anorexia nervosa; atypical antipsychotics (eg, olanzapine) have mixed/preliminary data and pharmacotherapy should not replace weight restoration and behavioral treatment.

AHRQ and subsequent reviews.

Pharmacotherapy for BED: Some agents (eg, lisdexamfetamine, bupropion, chromium, intranasal naloxone in early RCTs) show preliminary benefit for reducing binge episodes; evidence quality varies and further trials are needed.

Multiple RCTs and systematic reviews summarized.

Coverage of pharmacologic treatment is subject to plan and formulary rules. The policy lists pharmacotherapy as a medically necessary treatment option for anorexia, bulimia and binge‑eating disorder but notes that coverage of particular drugs may be subject to formulary restrictions. In addition, the policy explicitly warns that coverage of lisdexamfetamine for binge‑eating disorder may be excluded under plans that exclude medications to decrease or increase weight; reviewers and billing staff should confirm member benefit documents before authorizing or submitting claims.

The policy identifies the Mandometer residential program and the ION™ (Individual Optimal Nutrition) analysis/profile as interventions with limited or unestablished clinical value. The Mandometer program’s published evidence is largely from a single Swedish group and non‑comparative series; Aetna notes that effectiveness has not been established and that a randomized trial versus standard care is needed. Similarly, the ION profile is described as a broad panel of biochemical and nutrient measures for which there is a lack of evidence supporting clinical value in diagnosing or evaluating eating disorders. These modalities may therefore be treated as investigational or excluded depending on plan rules.

The policy highlights a safety concern for application of excitatory non‑invasive brain stimulation (notably rTMS) in anorexia nervosa: narrative reviews report a trend toward iatrogenic weight loss with excitatory NIBS in AN and conclude that excitatory stimulation may be contraindicated on theoretical and empirical grounds. This caution should inform clinical decision‑making and payer review of requests for rTMS in members with anorexia.

The document summarizes background research across many diagnostic and treatment approaches without making standalone coverage determinations for each. For several novel or emerging interventions (for example, residential programs, device‑based neuromodulation, and e‑therapies), the available studies are small, single‑center, or uncontrolled and thus insufficient to establish long‑term effectiveness. The policy therefore compiles the evidence base and flags modalities as experimental/investigational where peer‑reviewed data do not meet standards for established medical benefit.

The USPSTF‑commissioned systematic review cited in the policy limited its analysis to adolescents and adults without underweight or overt physical signs of an eating disorder; accordingly, evidence that is limited to under‑weight populations or to patients with physical signs (e.g., rapid weight loss, pubertal delay, bradycardia, oligomenorrhea or amenorrhea) was excluded from that review. The policy notes the USPSTF conclusion that current evidence is insufficient to determine the balance of benefits and harms of screening in adolescents and adults without signs or symptoms.

The policy lists numerous diagnostic tests and therapeutic approaches that are considered experimental and investigational because of insufficient peer‑reviewed evidence. Examples include: brain imaging (MRI, PET, SPECT) for diagnosis/treatment planning; a range of genetic polymorphism tests (COMT, ESR1, 5‑HTTLPR, MC4R); blood‑based serotonergic biomarkers; EEG for management; gut microbiota evaluation; the ION nutritional profiling; measurement of multiple peripheral biomarkers (BDNF, adiponectin, hypothalamic neuropeptides, polyunsaturated fatty acids); and measurements of serum zinc. On the treatment side, listed investigational therapies include acupuncture, ghrelin agonists, GLP‑1 receptor agonists, intranasal naloxone, liraglutide, neural therapy, biofeedback/neurofeedback, music therapy, Mandometer treatment, repetitive TMS, deep brain stimulation for refractory anorexia, and many others. These items are identified in the policy’s Experimental and Investigational section and should be handled as not medically necessary absent compelling peer‑reviewed evidence and applicable plan language.

A small randomized, double‑blind, sham‑controlled trial of rTMS in bulimia nervosa (Walpoth et al., n=14) found no additional benefit of active stimulation over sham on bingeing and purging or commonly used mood and obsessive‑compulsive scales. The policy cites these negative randomized data when listing repetitive transcranial magnetic stimulation for BN among investigational or not‑medically‑necessary interventions.

Within the excerpted material there are numerous statements identifying investigational procedures and summarizing evidence, but the text does not always include explicit formal determinations phrased as 'not medically necessary' for every intervention. Instead, the policy groups many interventions into an Experimental and Investigational list and states that items in that list are considered investigational because evidence is insufficient; reviewers should reference the Experimental and Investigational section for specific determinations rather than expect a separate 'not medically necessary' statement for each item in this excerpt.

Coding

Covered CPT/HCPCS codes if selection criteria are metmixedCovered

76977	Ultrasound bone density measurement and interpretation, peripheral site(s), any method.
77078	Computerized tomography, bone mineral density study, 1 or more sites.
77080	Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites.
77081	Dual energy x-ray absorptiometry (DXA), additional code (listed in range 77080 - 77081).
80047	Basic metabolic panel (Calcium, ionized).
80048	Basic metabolic panel (Calcium, total).
80050	General health panel.
80053	Comprehensive metabolic panel.
80076	Hepatic function panel.
81000	Urinalysis.

1–10 of 64

1/7

Codes listed as not covered / related not-covered groupsmixedNot Covered

70450	Computed tomography, head or brain (listed in range 70450 - 70470).
70496	Computed tomographic angiography, head, with contrast material(s).
70551	Magnetic resonance imaging, brain (listed in range 70551 - 70553).
70554	Functional MRI, brain (listed in range 70554 - 70555).
78600	Brain imaging (nuclear medicine) (listed in range 78600 - 78610).
81403	Molecular pathology procedure level 4.
84630	Zinc (measurement).
96900	Actinotherapy (ultraviolet light).
97812	Acupuncture subsequent sessions (listed in range 97810 - 97814).
A4633	Replacement bulb/lamp for ultraviolet light therapy system.

1–10 of 13

1/2

ICD-10 codesICD-10

F50.00	Anorexia nervosa.
F50.01	Anorexia nervosa, other.
F50.02	Anorexia nervosa, unspecified.
F50.2	Bulimia nervosa.
F50.81	Binge eating disorder.
F50.82	Avoidant/restrictive food intake disorder.
R63.0	Anorexia.
Z13.21	Encounter for screening for nutritional disorder [eating disorders] (listed as not covered).

No explicit billing codes in this excerptmixed

No codes listed

Anorexia weight threshold

Percent of expected body weight< 85% of expected body weight

BMI threshold noteConsider diagnosis with BMI ≤ 17.5 kg/m2

Clinical features (related)Disturbance in body image and, in post‑menarcheal females, amenorrhea

Bulimia frequency criterion

Minimum frequencyBinge eating with inappropriate compensatory behaviors ≥ 2 times per week

Minimum durationFor at least ≥ 3 months (average)

Typical compensatory behaviorsPurging, restriction, or excessive exercise following binge episodes

BMI inclusion for liraglutide trial

BMI inclusion for liraglutide trial>= 27 kg/m2

Trial duration and dose (pilot)17‑week trial of liraglutide 3.0 mg/day (pilot RCT)

Primary outcome contextOBEs/week (no significant difference); greater percent weight loss with liraglutide

Provider Actions & Administrative Notes

Billing Rule

Advanced procedures / implant coding noted

Advanced procedures and implant-related codes (e.g., deep brain stimulation CPT codes) are listed as not covered for indications in this CPB — verify coding and medical necessity prior to submission to avoid denials.

Not-covered CPT examples: 61863, +61864, 61867, +61868, 61880

Prior Authorization

Prior authorization for experimental/long-term programs

Prior authorization may be required for experimental, novel, or long-term residential/specialty programs (for example, unproven modalities like Mandometer residential programs). Submit clinical rationale, prior treatment history, objective measures of severity, and expected length of stay when requesting authorization.

Document prior outpatient treatment attempts and clinical need for higher level of care
Include program description and planned therapeutic components
Provide expected treatment duration and measurable goals

Prior Authorization

Lisdexamfetamine (Vyvanse) for BED

Lisdexamfetamine (Vyvanse) is an FDA‑approved pharmacotherapy for binge‑eating disorder (BED). Coverage may be subject to formulary restrictions or plan exclusions for weight‑altering medications; prior authorization may apply per benefit plan.

Check member's drug formulary and any PA or quantity limits
If PA required, provide BED diagnosis, prior therapies tried, and treatment goal

Note

Prior authorization not specified in excerpt

In the provided excerpts, no specific prior authorization requirements are explicitly stated for many services (e.g., enteral nutrition supplies, NG feeding). Treating providers should check the member's benefit plan and medical policy for any PA rules before providing services.

Verify benefit plan prior authorization rules for enteral nutrition and related supplies
Coding lists do not equate to PA approval — submit clinical documentation as needed

Note

Prior authorization not specified in provided text

Some coding entries and background sections note that prior authorization is not specified in the provided text (e.g., enteral nutrition HCPCS groups). This is informational; operational PA rules may be maintained separately.

Check administrative PA lists or pharmacy benefit for medication-specific requirements
Do not assume no PA — confirm with payer portal or policy documents

Note

Prior authorization not specified in this section

Within this section, no explicit prior authorization or utilization management rules are stated for several interventions (e.g., DBS, NG feeding, residential programs). Operational PA requirements should be confirmed with the payer.

Confirm PA requirements for investigational/high-cost procedures (e.g., DBS) before referral
When in doubt, submit pre-service review to avoid retrospective denials

Denial Risk

Screening code not covered

Screening for eating disorders (ICD-10 Z13.21) is designated as not covered in this CPB because screening clinical value has not been established in the literature presented.

Do not bill Z13.21 for covered diagnostic services under this CPB; use diagnostic codes when clinical disorder is identified

Denial Risk

Investigational modalities risk denial

Investigational modalities (for example, Mandometer programs, certain residential treatments, DBS for AN) carry a risk of denial because clinical value and long-term effectiveness have not been established.

Document rationale and evidence when requesting authorization for novel modalities
Be prepared for denials when therapies are labeled investigational in policy

Denial Risk

Lack of controlled trials showing long‑term effectiveness

There is a documented lack of controlled trials demonstrating long‑term effectiveness for some higher‑level care settings (notably residential treatment) and for several interventions, which may limit coverage justification for prolonged stays or novel programs.

Provide objective outcome data and justification for continued length of stay when requesting ongoing coverage
Consider step‑down to evidence‑based outpatient or PHP where appropriate

Note

Not applicable in this excerpt — no explicit operational rules

Not applicable in this excerpt: no explicit step therapy or formal utilization management rules are detailed. Use the policy content as clinical guidance and consult administrative PA/UM documents for operational rules.

Operational rules (PA, step therapy) may be maintained separately from this CPB
Contact payer UM team for program‑specific authorization criteria

Note

No explicit authorization or prior‑approval stated

The excerpt does not state explicit authorization or prior‑approval processes for many services; providers must verify PA requirements through the payer's administrative channels.

Confirm PA for high‑cost medications, implants, and residential services before initiating treatment
Include supporting clinical documentation with any PA request

Documentation Required

Required assessment documentation

Required assessment documentation for medical necessity determinations should include medical history and physical exam details, psychiatric/psychological evaluation, relevant labs (CBC, electrolytes, BUN/creatinine, LFTs), EKG results, and bone density testing when indicated.

Include baseline weight/percent expected body weight and recent weight trend
Attach relevant lab results and EKG when requesting higher level of care or enteral nutrition

Documentation Required

Bone health therapy documentation

When documenting bone‑health therapies (e.g., bisphosphonates, hormone replacement), include rationale, prior efforts at weight restoration, bone mineral density results, fracture history, and discussion of limited evidence and risks.

Document failure of or contraindication to weight restoration when proposing bone‑targeted therapy
Note informed consent discussing uncertain benefit and potential risks

Documentation Required

When naso‑gastric feeding is used for AN

When naso‑gastric (NG) feeding is used for anorexia nervosa, document the indication (e.g., life‑threatening malnutrition or failure of oral refeeding), short‑term weight gain goals, monitoring plan (electrolytes, refeeding protocol), and adherence issues.

Provide daily caloric targets and expected rate of weight gain
Document monitoring for refeeding syndrome and prophylactic measures (eg, phosphate supplementation)

Note

No explicit documentation or medical necessity template provided

No explicit documentation templates or medical necessity checklists are provided in the excerpts; use the assessment and treatment elements noted in the policy as the basis for documentation submitted for authorizations.

Supply clinical notes, lab results, psychiatry/psychology evaluations, and prior treatment chronology when requesting authorization

Step Therapy

Pharmacotherapy sequencing note

Pharmacotherapy sequencing: prioritize weight restoration and evidence‑based psychosocial therapies for anorexia nervosa before initiating pharmacologic treatments; for bulimia, use evidence‑based agents (e.g., fluoxetine) as first‑line when indicated.

For AN: emphasize nutritional rehabilitation and psychotherapy before meds
For BN: consider fluoxetine before other agents unless contraindicated

Step Therapy

Step from evidence‑based therapy to experimental medications

When considering experimental or off‑label medications, step from established evidence‑based therapies to novel agents only after documented failure or intolerance of first‑line treatments; include risk/benefit discussion and safety monitoring plan.

Document prior trials of psychotherapy and approved/standard pharmacotherapies
Include monitoring plan for adverse effects and objective outcome measures

Step Therapy

Medication selection considerations

Medication selection considerations: fluoxetine is the only FDA‑approved medication for bulimia nervosa; other agents (eg, topiramate, bupropion, lisdexamfetamine) have mixed evidence or specific safety concerns that should be documented when used.

Avoid bupropion in bulimia due to seizure risk
When using topiramate or stimulants, document informed consent and monitor for adverse events

Note

No formal step‑therapy rules are specified

No formal step‑therapy rules are specified in the provided excerpts; the document summarizes trial evidence and clinical guidance but does not prescribe utilization management sequencing.

Operational step therapy, if any, should be confirmed via administrative PA criteria

Note

No step‑therapy rules are described in the text

Several study summaries describe pharmacotherapy trials and suggested sequences, but no operational step‑therapy rules are described in the text — these are clinical references, not UM directives.

Use clinical trial evidence to support medical necessity but verify payer's step therapy lists separately

Definitions

Anorexia nervosa definition

Core weight criterionRefusal/ failure to maintain minimally normal weight — e.g., <85% of expected body weight

BMI considerationConsider diagnosis with BMI ≤ 17.5 kg/m2 (young woman with amenorrhea)

Associated clinical featuresDisturbance of body image and, in post‑menarcheal females, amenorrhea (absence of 3 consecutive cycles)

Bulimia nervosa definition

Binge and compensatory behavior definitionRecurrent binge eating with inappropriate compensatory behaviors (purging, restriction, excessive exercise)

Frequency and timeframeOccurs on average at least twice weekly for ≥3 months

Typical weight statusIndividuals are generally in the normal weight range despite recurrent weight changes

Anorexia nervosa (AN) — evidence context

Medication roleNo medications have proven efficacy for acute anorexia nervosa; pharmacotherapy has a limited role

Behavioral therapiesBehavioral therapies may help prevent relapse and offer limited benefits

Clinical priorityWeight restoration and medical stabilization are essential components of treatment

Bulimia nervosa (BN) — evidence context

Responsive treatmentsBulimia nervosa responds to certain medications (fluoxetine) and behavioral therapies

FDA‑approved medicationFluoxetine is the only medication approved for bulimia nervosa

Combination therapy guidanceEvidence provides limited guidance on combining medications with behavioral treatments

Binge‑eating disorder (BED) — pharmacologic agents and evidence

Pharmacologic agents with RCT dataLisdexamfetamine, bupropion, chromium (pilot data) show preliminary efficacy for BED

Evidence variabilityQuality and outcomes vary across agents (binge frequency, weight, metabolic markers) and trials are often small

Harms and monitoringPharmacotherapies can reduce symptoms but are associated with adverse effects and require clinician judgment

Night eating syndrome (NES) — definition

Core definitionNight eating syndrome (NES) is a delayed pattern of food intake with recurrent nocturnal eating and/or excessive consumption after the evening meal

Clinical associationsAssociated with obesity, sleep disturbances, and psychiatric comorbidity

Assessment tools and treatmentsUse Night Eating Questionnaire; antidepressants and psychological therapies may be used; melatonergic meds and light therapy hold promise

BED — lisdexamfetamine approval and indication

Regulatory approvalLisdexamfetamine is FDA‑approved for adult moderate‑to‑severe BED (first FDA‑approved medication for BED, Jan 30, 2015)

Supporting trialsEfficacy shown in 2 clinical studies (724 adults) with decreased binge days and obsessive‑compulsive binge behaviors

Clinical use noteRCT evidence supports benefit; prior authorization or benefit exclusion may apply depending on plan formularies

COMT Val158Met polymorphism — genetics note

Genetic polymorphism examinedCOMT Val158Met variant evaluated for association with eating disorders

Meta‑analysis resultMeta‑analysis pooling 11 studies (7,225 subjects) found no significant association with AN or BN

InterpretationCurrent evidence does not support COMT Val158Met as a diagnostic marker for EDs

NG enteral nutrition — definition and usage

Definition and purposeNG enteral nutrition = nasogastric tube feeding used for refeeding and weight restoration in anorexia nervosa

Evidence on effectivenessMultiple studies reported average weight gain >1 kg/week and increased caloric intake versus oral‑only feeding

Safety considerationsProphylactic phosphate supplementation in several studies reduced refeeding hypophosphatemia to <1%

SCOFF — screening tool and performance

Tool descriptionSCOFF is a brief screening questionnaire for eating disorders (cut‑point ≥2)

Performance metrics (adults)Pooled sensitivity 84% (95% CI:74–90%); pooled specificity 80% (95% CI:65–89%)

Context of useAdequate accuracy for detecting eating disorders among adults; no trials evaluated benefits/harms of screening

YBOCS‑BE — outcome measure

Measure descriptionYBOCS‑BE = Yale‑Brown Obsessive Compulsive Scale modified for binge eating

Use in trialsUsed as an outcome measure in BED trials; lisdexamfetamine and topiramate trials reported changes on YBOCS‑BE

InterpretationPooled MDs indicate pharmacotherapies reduced YBOCS‑BE scores versus placebo in referred BED populations

Eating disorders — examples

Examples listedEating disorders include anorexia nervosa (AN), bulimia nervosa (BN), and binge‑eating disorder (BED)

Definition summaryPsychiatric conditions defined by disturbances in eating or eating‑related behaviors impairing physical or psychosocial functioning

Prevalence notesLifetime prevalence estimates vary by disorder and sex (see source for detailed rates)

SCOFF questionnaire — screening accuracy

Duplicate entry noteSCOFF questionnaire (cut‑point ≥2) — pooled sensitivity 84% and specificity 80% in adults

Evidence sourceMeta‑analysis of test accuracy studies included in USPSTF‑related review (10 studies, n=3,684 adults)

Screening trial gapNo included studies directly assessed benefits/harms of screening programs in asymptomatic populations

Treatment Modalities

inv-70: Psychotherapy, Nutritional Counseling, Pharmacotherapy

Psychotherapy: Cognitive behavioral therapy, family psychotherapy, interpersonal psychotherapy, and psychodynamic psychotherapy are core, medically necessary modalities.

Primary behavioral treatments; indicated across eating disorder presentations as clinically appropriate.

Nutritional counseling with a graduated eating plan tied to specific weight goals and monitoring is essential; enteral nutrition reserved as last resort for anorexia.

Nutrition emphasized as central intervention.

Pharmacotherapy roles defined by disorder: limited role in anorexia (SSRIs, antipsychotics have mixed evidence); fluoxetine for bulimia; lisdexamfetamine and other agents for BED per trial evidence and approval status.

Subject to formulary restrictions and benefit exclusions for weight‑altering medications.

inv-71: rTMS

rTMS evidence and status: A small sham‑controlled RCT in bulimia (Walpoth et al.) found no benefit over placebo; neurostimulation approaches show preliminary promise but lack large, well‑conducted RCTs and are considered investigational for routine use.

Excitatory NIBS may be contraindicated in anorexia due to a trend toward iatrogenic weight loss in some reports.

inv-72: Residential behavioral program (Mandometer)

Mandometer residential program status: Mandometer is a residential program (~12 months) combining meal biofeedback, heat therapy, activity restriction and social reconstruction; effectiveness has not been established in RCTs versus standard care and remains investigational.

Evidence primarily from single‑group reports and limited trials; not validated as standard care.

inv-73: Pharmacologic (BED)

Pharmacologic options for BED: Lisdexamfetamine has RCT evidence and FDA approval for adult BED; other agents including bupropion, chromium, intranasal naloxone, and topiramate have RCT or pilot data showing variable efficacy and safety; selection requires clinician judgment and monitoring.

Lisdexamfetamine trials demonstrated reductions in binge days; topiramate reduced binge frequency but had higher withdrawal for adverse effects.

inv-74: Non-invasive and invasive brain stimulation

Neurostimulation evidence summary: Non‑invasive and invasive brain stimulation (rTMS, tDCS, DBS) show preliminary promise for ED symptoms and craving modulation but evidence is limited, heterogeneous, and lacking large RCTs; parameters and targets require further study.

DBS has small observational data in treatment‑refractory AN; rTMS/tDCS findings mixed and further trials needed.

inv-75: Bright light therapy

Bright light therapy status: Bright light therapy may acutely improve disordered eating behavior and mood in disorders with circadian features (eg, night eating); timing and durability of effect remain uncertain and further research is needed.

Systematic review identified small studies with short‑term benefit.

inv-76: Behavioral inhibition training

Behavioral inhibition training status: Food‑specific inhibition training improved inhibitory control in a small RCT for BED and was feasible; clinical efficacy requires larger confirmatory trials.

Pilot proof‑of‑concept data support further study.

inv-77: Pharmacologic treatments

Pharmacologic treatments summary: Fluoxetine is the only FDA‑approved medication for bulimia; antipsychotics have mixed data in anorexia; pharmacotherapy is adjunctive to psychotherapy and nutrition, not a substitute for weight restoration in AN.

Guideline and evidence review consensus.

inv-78: Ghrelin agonists (relamorelin)

Ghrelin agonists evidence: Relamorelin decreased gastric emptying time and showed a trend toward weight gain after 4 weeks in a small RCT (n=22); further study needed to establish safety and efficacy.

Preliminary randomized data; not established therapy.

inv-79: GLP-1 receptor agonists

GLP-1 receptor agonists status: GLP‑1 receptor agonists are hypothesized to reduce binge eating with biologic rationale and preliminary data; randomized placebo‑controlled trials are proposed but definitive efficacy data are lacking in this excerpt.

Research and pilot data support further trials.

inv-80: Phentermine/topiramate ER (Qsymia)

Phentermine/topiramate ER (Qsymia) evidence: Small randomized and cross‑over trials reported PHEN/TPM‑ER reduced binge eating days and increased abstinence versus placebo in predominantly BED patients; BN sample sizes were very small making conclusions for BN uncertain.

Preliminary RCT evidence; further study required for routine use in EDs.

inv-81: Enteral nutrition (nasogastric tube) for AN

Enteral nutrition (NG) for AN: Nasogastric enteral nutrition increased caloric intake and commonly achieved >1 kg/week weight gain in multiple studies; prophylactic phosphate supplementation reduced refeeding hypophosphatemia incidence to <1% in studies reporting it.

Used in hospital settings for medical refeeding when oral intake insufficient or life‑threatening condition exists.

inv-82: Neural therapy (superficial injection)

Neural therapy status: Neural therapy (superficial local anesthetic injection) has anecdotal case‑report evidence (n=2) suggesting rapid response in bulimia but lacks controlled replication and remains investigational.

Evidence limited to case reports; controlled studies needed.

inv-83: Oxytocin (intranasal)

Oxytocin status: Intranasal oxytocin modulates eating behavior and social/cognitive domains in preliminary studies; therapeutic evidence in AN, BN, and BED is limited and investigational.

Pilot and early‑phase data only.

inv-84: Enteral Nutrition (NG)

Enteral Nutrition (NG) summary: NG feeding in AN resulted in increased caloric intake and weight gain versus oral‑only strategies in several studies; evidence supports efficacy in inpatient refeeding but long‑term outcomes require further study.

Enteral nutrition considered when clinically indicated; closely monitored in hospital settings.

inv-85: Pharmacotherapy (lisdexamfetamine, topiramate)

Pharmacotherapy trials (lisdexamfetamine, topiramate): Lisdexamfetamine demonstrated reductions in binge frequency in multiple RCTs and is FDA‑approved for adult BED; topiramate reduced binge episodes and weight in meta‑analysis but had higher withdrawal rates for adverse events—both require monitoring for harms.

Evidence includes multiple RCTs and meta‑analyses summarized.

inv-86: Neurofeedback / EEG / Biofeedback

Neurofeedback/EEG/Biofeedback: Preliminary and heterogeneous studies of neurofeedback, EEG‑guided interventions and biofeedback indicate possible effects on dysfunctional eating behaviors and brain activity in BED/obesity but evidence is limited and not definitive.

Systematic reviews report small number of heterogeneous studies; further research needed.

inv-87: Gut microbiota evaluation / interventions

Gut microbiota interventions: Studies report intestinal dysbiosis in anorexia with lower microbial diversity; fecal microbiota transplantation and other microbiota‑directed interventions remain investigational with inconsistent evidence.

Research findings are preliminary and methods heterogeneous.

inv-88: Pharmacologic, neuromodulation, psychosocial (music therapy)

Multi‑modality experimental approaches: Various pilot or early‑phase interventions (pharmacologic agents not yet established, neuromodulation techniques, and psychosocial approaches such as music therapy) have shown limited or preliminary benefits in small heterogeneous studies and should be considered investigational until larger confirmatory trials are available.

Examples include liraglutide pilot trials, DBS for refractory AN (small observational studies), and music‑based interventions with limited generalizability.

inv-89: Various modalities (pharmacotherapy, psychotherapy, neuromodulation, nutritional support)

Various modalities summary: The evidence base includes randomized trials and systematic reviews of pharmacotherapies (eg, lisdexamfetamine, topiramate), psychotherapies, electrical and magnetic neuromodulation (rTMS, tDCS, DBS), and nutritional/enteral feeding interventions; many promising modalities remain preliminary and require larger, well‑conducted trials to establish clinical effectiveness and safety.

Refer to cited references for detailed trial data and systematic reviews.

OpenPayer

Eating Disorders

Coverage Criteria

Coding

Provider Actions & Administrative Notes

Background

Definitions

Level of Care Criteria

Treatment Modalities

Visit Limits

References & Revision History